CL2011001178A1 - Uso de (r)-7-cloro-niquinuclidin-3-1l)senzo[b]tiofen0-2-carboxamida o una sal de la misma o una composicion farmaceutica que la comprende para preparar un medicamento util para mejorar la cognicion en un paciente que sufre de alzheimer o esquizofrenia. - Google Patents

Uso de (r)-7-cloro-niquinuclidin-3-1l)senzo[b]tiofen0-2-carboxamida o una sal de la misma o una composicion farmaceutica que la comprende para preparar un medicamento util para mejorar la cognicion en un paciente que sufre de alzheimer o esquizofrenia.

Info

Publication number: CL2011001178A1
Authority: CL; Chile
Prior art keywords: carboxamide; thiophene; chloro; salt; niquinuclidin
Prior art date: 2008-11-19

Application number

CL2011001178A

Other languages

English (en)

Spanish (es)

Inventor

Gerhard Koenig

Richard Chesworth

Gideon Shapiro

Original Assignee

Forum Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-11-19

Filing date

2011-05-19

Publication date

2011-10-14

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41786120&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2011001178(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2011-05-19 Application filed by Forum Pharmaceuticals Inc filed Critical Forum Pharmaceuticals Inc

2011-10-14 Publication of CL2011001178A1 publication Critical patent/CL2011001178A1/es

Links

230000019771 cognition Effects 0.000 title abstract 2
150000003839 salts Chemical class 0.000 title abstract 2
229940079593 drug Drugs 0.000 title 1
239000003814 drug Substances 0.000 title 1
239000008194 pharmaceutical composition Substances 0.000 title 1
201000000980 schizophrenia Diseases 0.000 title 1
DENPQNAWGQXKCU-UHFFFAOYSA-N thiophene-2-carboxamide Chemical compound NC(=O)C1=CC=CS1 DENPQNAWGQXKCU-UHFFFAOYSA-N 0.000 title 1
SSRDSYXGYPJKRR-ZDUSSCGKSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-7-chloro-1-benzothiophene-2-carboxamide Chemical compound C1N(CC2)CCC2[C@H]1NC(=O)C1=CC(C=CC=C2Cl)=C2S1 SSRDSYXGYPJKRR-ZDUSSCGKSA-N 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4462—Non condensed piperidines, e.g. piperocaine only substituted in position 3
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Neurosurgery (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Psychiatry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

CL2011001178A 2008-11-19 2011-05-19 Uso de (r)-7-cloro-niquinuclidin-3-1l)senzo[b]tiofen0-2-carboxamida o una sal de la misma o una composicion farmaceutica que la comprende para preparar un medicamento util para mejorar la cognicion en un paciente que sufre de alzheimer o esquizofrenia. CL2011001178A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US11610608P	2008-11-19	2008-11-19

Publications (1)

Publication Number	Publication Date
CL2011001178A1 true CL2011001178A1 (es)	2011-10-14

Family

ID=41786120

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
CL2011001178A CL2011001178A1 (es)	2008-11-19	2011-05-19	Uso de (r)-7-cloro-niquinuclidin-3-1l)senzo[b]tiofen0-2-carboxamida o una sal de la misma o una composicion farmaceutica que la comprende para preparar un medicamento util para mejorar la cognicion en un paciente que sufre de alzheimer o esquizofrenia.
CL2017001853A CL2017001853A1 (es)	2008-11-19	2017-07-18	Tratamiento de trastornos cognitivos con (r)-7-cloro-n-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida y sales farmacéuticamente aceptables de la misma (divisional de solicitud n°1707-2016).
CL2018001420A CL2018001420A1 (es)	2008-11-19	2018-05-25	Tratamiento de trastornos cognitivos con (r)-7-cloro-n-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida y sales farmacéuticamente aceptables de la misma. (divisional solicitud 201701853)

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
CL2017001853A CL2017001853A1 (es)	2008-11-19	2017-07-18	Tratamiento de trastornos cognitivos con (r)-7-cloro-n-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida y sales farmacéuticamente aceptables de la misma (divisional de solicitud n°1707-2016).
CL2018001420A CL2018001420A1 (es)	2008-11-19	2018-05-25	Tratamiento de trastornos cognitivos con (r)-7-cloro-n-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida y sales farmacéuticamente aceptables de la misma. (divisional solicitud 201701853)

Country Status (34)

Country	Link
US (6)	US8642638B2 (it)
EP (4)	EP2355822B1 (it)
JP (6)	JP5272080B2 (it)
KR (3)	KR20110091549A (it)
CN (3)	CN105687191A (it)
AU (1)	AU2009316557B2 (it)
BR (1)	BRPI0922057A2 (it)
CA (3)	CA2744278C (it)
CL (3)	CL2011001178A1 (it)
CO (1)	CO6400190A2 (it)
CR (1)	CR20110267A (it)
CY (3)	CY1113671T1 (it)
DK (3)	DK2540297T3 (it)
EC (1)	ECSP11011076A (it)
ES (3)	ES2396300T3 (it)
HR (3)	HRP20130007T1 (it)
HU (2)	HUE026815T2 (it)
IL (5)	IL212921A (it)
LT (1)	LT2889033T (it)
MX (1)	MX2011005270A (it)
MY (2)	MY159826A (it)
NZ (2)	NZ613291A (it)
PE (1)	PE20110711A1 (it)
PH (2)	PH12014501629A1 (it)
PL (3)	PL2889033T3 (it)
PT (3)	PT2355822E (it)
RS (1)	RS52583B (it)
RU (3)	RU2532327C2 (it)
SG (1)	SG10201504102QA (it)
SI (3)	SI2540297T1 (it)
SM (3)	SMT201800308T1 (it)
TR (1)	TR201807944T4 (it)
WO (1)	WO2010059844A1 (it)
ZA (1)	ZA201104044B (it)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE10164139A1 (de)	2001-12-27	2003-07-10	Bayer Ag	2-Heteroarylcarbonsäureamide
LT2889033T (lt)	2008-11-19	2018-07-10	Forum Pharmaceuticals Inc.	Šizofrenijos negatyvių simptomų gydymas (r)-7-chlor-n-(chinuklidin-3-il)benzo[b]tiofen-2-karboksamidu ir jo farmaciniu požiūriu priimtinomis druskomis
PE20170923A1 (es)	2010-05-17	2017-07-12	Forum Pharmaceuticals Inc	Una forma cristalina de clorhidrato de (r)-7-cloro-n-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida monohidratado
EP2640378A4 (en) *	2010-11-18	2014-05-21	Envivo Pharmaceuticals Inc	INFLAMMATION TREATMENT WITH CERTAIN NICOTINIC ACID ALPHA-7 RECEPTOR AGONISTS IN COMBINATION WITH ACETYLCHOLINESTERASE INHIBITORS
EP2706854A4 (en) *	2011-05-09	2014-12-03	Envivo Pharmaceuticals Inc	TREATMENT OF COGNITIVE DISORDERS BY CERTAIN AGONISTS OF THE ALPHA-7 NICOTINIC RECEPTOR IN COMBINATION WITH NICOTINE
CA2840746A1 (en) *	2011-07-01	2013-01-10	Envivo Pharmaceuticals, Inc.	Methods of treatment of limited cognitive impairment
EP3461481A1 (en) *	2012-05-08	2019-04-03	Forum Pharmaceuticals Inc.	Methods of maintaining, treating or improving cognitive function
ES3002659T3 (en)	2017-02-27	2025-03-07	Univ Of Pittsburgh Of The Commonwealthsystem Of Higher Education	Anti-psychotic composition and treatment methods
WO2019060298A1 (en)	2017-09-19	2019-03-28	Neuroenhancement Lab, LLC	METHOD AND APPARATUS FOR NEURO-ACTIVATION
US11717686B2 (en)	2017-12-04	2023-08-08	Neuroenhancement Lab, LLC	Method and apparatus for neuroenhancement to facilitate learning and performance
US11478603B2 (en)	2017-12-31	2022-10-25	Neuroenhancement Lab, LLC	Method and apparatus for neuroenhancement to enhance emotional response
US12280219B2 (en)	2017-12-31	2025-04-22	NeuroLight, Inc.	Method and apparatus for neuroenhancement to enhance emotional response
US11364361B2 (en)	2018-04-20	2022-06-21	Neuroenhancement Lab, LLC	System and method for inducing sleep by transplanting mental states
US11452839B2 (en)	2018-09-14	2022-09-27	Neuroenhancement Lab, LLC	System and method of improving sleep

Family Cites Families (113)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5122528A (en)	1983-12-22	1992-06-16	Erbamont, Inc.	Analgesic use of benzobicyclic carboxamides
US4605652A (en)	1985-02-04	1986-08-12	A. H. Robins Company, Inc.	Method of enhancing memory or correcting memory deficiency with arylamido (and arylthioamido)-azabicycloalkanes
EP0201165B1 (en)	1985-03-14	1994-07-20	Beecham Group Plc	Medicaments for the treatment of emesis
HU895334D0 (en)	1986-07-30	1990-01-28	Sandoz Ag	Process for the preparation of nasal pharmaceutical compositions
DE3827253A1 (de)	1987-08-20	1989-03-02	Sandoz Ag	Ester und amide von cyclischen carbonsaeuren und cyclischen alkoholen und aminen sowie verfahren zu deren herstellung und sie enthaltende therapeutische zusammensetzungen
DE3740984A1 (de)	1987-12-03	1989-06-15	Sandoz Ag	N-oxide von heterocyclischen carbonsaeurederivaten bzw. verfahren zu deren herstellung und deren verwendung
NZ227229A (en)	1987-12-10	1991-03-26	Duphar Int Res	Indole derivatives and pharmaceutical compositions
US5198437A (en)	1987-12-10	1993-03-30	Duphar International Research B.V.	1,7-annelated indolecarboxylic acid esters and amides
US4863919A (en)	1988-02-01	1989-09-05	A. H. Robins Company, Incorporated	Method of enhancing memory or correcting memory deficiency with arylamido(and arylthiomido)-azabicycloalkanes
DE3810552A1 (de)	1988-03-29	1989-10-19	Sandoz Ag	Ester und amide von indol-, benzo(b)thiopen-, benzo(b)furancarbonsaeuren oder 4-amino-2-methoxy-benzolsaeuren mit n-heterocyclischen oder n-heterobicyclischen alkoholen oder aminen, verfahren zu deren herstellung sie enthaltende pharmazeutische zusammensetzungen sowie applikator zur verabreichung derselben
EP0353371A1 (en)	1988-08-04	1990-02-07	Synthelabo	Memory enhancing-R-N-(1-azabicyclo[2.2.2] oct-3-yl) benzamides and thiobenzamides
IE62662B1 (en)	1989-01-06	1995-02-22	Elan Corp Plc	Use of nicotine in the treatment of conditions susceptible to said treatment
US5189041A (en)	1990-11-16	1993-02-23	Syntex (U.S.A.) Inc.	Tricyclic 5-ht3 receptor antagonists
US5114947A (en)	1990-12-27	1992-05-19	Erbamont Inc.	Method for alleviating anxiety using benzobicyclic carboxamides
DE4115215A1 (de)	1991-05-10	1992-11-12	Merck Patent Gmbh	Indolderivate
SE9201478D0 (sv)	1992-05-11	1992-05-11	Kabi Pharmacia Ab	Heteroaromatic quinuclidinenes, their use and preparation
US5977144A (en)	1992-08-31	1999-11-02	University Of Florida	Methods of use and compositions for benzylidene- and cinnamylidene-anabaseines
ATE192157T1 (de)	1994-08-24	2000-05-15	Astra Ab	Therapeutisch verwendbare spiro-azabicyclische verbindungen
US5703116A (en)	1995-04-18	1997-12-30	Geron Corporation	Telomerase Inhibitors
US5863936A (en)	1995-04-18	1999-01-26	Geron Corporation	Telomerase inhibitors
US5760062A (en)	1995-04-18	1998-06-02	Geron Corporation	Telomerase inhibitors
US5656638A (en)	1995-04-18	1997-08-12	Geron Corporation	Telomerase inhibitors
GB9606736D0 (en)	1996-02-19	1996-06-05	Shire International Licensing	Therapeutic method
FR2756826B1 (fr)	1996-12-05	1999-01-08	Adir	Nouveaux derives tetrahydropyridiniques substitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
KR100589872B1 (ko)	1997-05-30	2006-06-15	뉴로서치 에이/에스	8-아자비사이클로(3,2,1)옥트-2-엔 유도체 및 이의 제조방법
US7214686B2 (en)	1997-06-30	2007-05-08	Targacept, Inc.	Pharmaceutical compositions and methods for effecting dopamine release
JPH1180027A (ja)	1997-09-12	1999-03-23	Dai Ichi Seiyaku Co Ltd	向知性薬
US6875606B1 (en)	1997-10-23	2005-04-05	The United States Of America As Represented By The Department Of Veterans Affairs	Human α-7 nicotinic receptor promoter
US6277870B1 (en)	1998-05-04	2001-08-21	Astra Ab	Use
AU6394399A (en)	1998-09-18	2000-04-10	Rockefeller University, The	Lynx, a novel family of receptor ligands in the central nervous system, corresponding nucleic acids and proteins and uses thereof
US6432975B1 (en)	1998-12-11	2002-08-13	Targacept, Inc.	Pharmaceutical compositions and methods for use
US6953855B2 (en)	1998-12-11	2005-10-11	Targacept, Inc.	3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof
SE9900100D0 (sv)	1999-01-15	1999-01-15	Astra Ab	New compounds
FR2790474B1 (fr)	1999-03-05	2001-04-06	Synthelabo	Derives de pyridopyranoazepines, leur preparation et leur application en therapeutique
FR2791678B1 (fr)	1999-03-30	2001-05-04	Synthelabo	Derives de 1,4-diazabicyclo [3.2.2] nonane-4-carboxylates et -carboxamides, leur preparation et leur application en therapeutique
US6416735B1 (en)	1999-11-08	2002-07-09	Research Triangle Institute	Ligands for α-7 nicotinic acetylcholine receptors based on methyllcaconitine
EP1233979A1 (en)	1999-12-01	2002-08-28	Ortho-McNeil Pharmaceutical, Inc.	Method of diagnosing neurodegenerative disease
CA2393538A1 (en)	1999-12-14	2001-06-21	Pharmacia & Upjohn Company	Human ion channels
FR2804430B1 (fr)	2000-01-28	2002-03-22	Sanofi Synthelabo	Derives de 4-heteroaryl-1,4-diazabicyclo[3.2.2] nonane, leur preparation et leur application en therapeutique
GB0010955D0 (en)	2000-05-05	2000-06-28	Novartis Ag	Organic compounds
BR0111377A (pt)	2000-06-06	2003-06-03	Pfizer Prod Inc	Derivados de tiofeno úteis como agentes anticancerìgenos
TW593223B (en)	2000-06-20	2004-06-21	Merz Pharma Gmbh & Co Kgaa	1-amino-alkylcyclohexanes as 5-HT3 and neuronal nicotinic receptor antagonists
FR2810664B1 (fr)	2000-06-27	2004-12-24	Adir	Nouveaux composes cyclopropaniques 1,1 et 1,2-dissubstitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JP4616971B2 (ja)	2000-07-18	2011-01-19	田辺三菱製薬株式会社	１−アザビシクロアルカン化合物およびその医薬用途
US20030092613A1 (en)	2000-08-14	2003-05-15	Lee Daniel H. S.	Alpha7 nicotinic receptor peptides as ligands for beta amyloid peptides
US6479510B2 (en)	2000-08-18	2002-11-12	Pharmacia & Upjohn Company	Quinuclidine-substituted aryl compounds for treatment of disease
AU2001284645A1 (en)	2000-08-18	2002-03-04	Pharmacia And Upjohn Company	Quinuclidine-substituted aryl compounds for treatment of disease
US6492385B2 (en)	2000-08-18	2002-12-10	Pharmacia & Upjohn Company	Quinuclidine-substituted heteroaryl moieties for treatment of disease
AU2001282875A1 (en)	2000-08-21	2002-03-04	Pharmacia And Upjohn Company	Quinuclidine-substituted heteroaryl moieties for treatment of disease
DE10044905A1 (de)	2000-09-12	2002-03-21	Merck Patent Gmbh	(2-Azabicyclo[2.2.1]hept-7-yl)methanol-Derivate als nikontinische Acetylcholinrezeptor Agonisten
US20020086871A1 (en)	2000-12-29	2002-07-04	O'neill Brian Thomas	Pharmaceutical composition for the treatment of CNS and other disorders
ATE348829T1 (de)	2001-02-06	2007-01-15	Pfizer Prod Inc	Pharmazeutische zusammensetzungen zur behandlung von störungen des zns oder anderen erkrankungen
GB0108337D0 (en)	2001-04-03	2001-05-23	Novartis Ag	Organic compounds
US6569865B2 (en)	2001-06-01	2003-05-27	Astrazeneca Ab	Spiro 1-azabicyclo[2.2.2]octane-3,2′(3′h)-furo[2,3-b]pyridine
AR036040A1 (es)	2001-06-12	2004-08-04	Upjohn Co	Compuestos de heteroarilo multiciclicos sustituidos con quinuclidinas y composiciones farmaceuticas que los contienen
JP2005504059A (ja)	2001-08-24	2005-02-10	ファルマシアアンドアップジョンカンパニーリミティドライアビリティーカンパニー	疾患を処置するための置換アリール７−アザ［２．２．１］ビシクロヘプタン
JP2003081978A (ja)	2001-09-10	2003-03-19	Mitsubishi Pharma Corp	スピロ環式化合物およびその医薬用途
DE60218493D1 (de)	2001-09-12	2007-04-12	Pharmacia & Upjohn Co Llc	Substituierte 7-aza-ä2.2.1übicycloheptane für die behandlung von krankheiten
CA2462453C (en)	2001-10-02	2009-07-28	Pharmacia & Upjohn Company	Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease
JP2005511574A (ja)	2001-10-26	2005-04-28	ファルマシアアンドアップジョンカンパニーリミティドライアビリティーカンパニー	Ｎａｃｈｒアゴニストとしてのｎ−アザビシクロ−置換ヘテロ二環式カルボキサミド
CA2466375A1 (en)	2001-11-08	2003-05-15	Pharmacia & Upjohn Company	Azabicyclic-substituted-heteroaryl compounds for the treatment of disease
GB0127008D0 (en)	2001-11-09	2002-01-02	Novartis Ag	Organic compounds
MXPA04004373A (es)	2001-11-09	2004-08-11	Upjohn Co	Compuestos heterociclicos condensados con fenilo azabiciclo para el tratamiento de enfermedades.
DE10156719A1 (de)	2001-11-19	2003-05-28	Bayer Ag	Heteroarylcarbonsäureamide
FR2832712B1 (fr)	2001-11-23	2004-02-13	Sanofi Synthelabo	Derives de 4-(oxadiazol-3-yl)-1,4-diazabicyclo[3.2.2]nonane, leur preparation et leur application en therapeutique
FR2832713B1 (fr)	2001-11-23	2004-02-13	Sanofi Synthelabo	Derives de 4-(1,3,4-thiadiazol-2-yl)-1,4-diazabicyclo[3.2.2] nonane, leur preparation et leur application en therapeutique
FR2832714B1 (fr)	2001-11-23	2004-07-16	Sanofi Synthelabo	Derives de 4-(oxazolopyridin-2-yl)-1,4-diazabicyclo[3.2.2] nonane, leur preparation et leur application en therapeutique
HUP0501017A3 (en)	2001-12-14	2010-06-28	Targacept	Methods and compositions for treatment of central nervous system disorders
DE10162375A1 (de)	2001-12-19	2003-07-10	Bayer Ag	Bicyclische N-Aryl-amide
DE10162442A1 (de)	2001-12-19	2003-07-03	Bayer Ag	Monocyclische N-Aryl-amide
DE10164139A1 (de) *	2001-12-27	2003-07-10	Bayer Ag	2-Heteroarylcarbonsäureamide
EP1480977A2 (en)	2002-02-15	2004-12-01	PHARMACIA & UPJOHN COMPANY	Substituted aryl compounds for treatment of disease
CA2476624A1 (en)	2002-02-19	2003-08-28	Pharmacia & Upjohn Company	Azabicyclic compounds for the treatment of disease
CA2476681A1 (en)	2002-02-19	2003-08-28	Bruce N. Rogers	Fused bicyclic-n-bridged-heteroaromatic carboxamides for the treatment of disease
WO2003072578A1 (en)	2002-02-20	2003-09-04	Pharmacia & Upjohn Company	Azabicyclic compounds with alfa7 nicotinic acetylcholine receptor activity
DE10211416A1 (de)	2002-03-15	2003-09-25	Bayer Ag	Essig- und Propionsäureamide
DE10211415A1 (de)	2002-03-15	2003-09-25	Bayer Ag	Bicyclische N-Biarylamide
US20030236287A1 (en)	2002-05-03	2003-12-25	Piotrowski David W.	Positive allosteric modulators of the nicotinic acetylcholine receptor
US7358057B2 (en)	2002-05-09	2008-04-15	Memory Pharmaceuticals Corporation	QM-7 and QT-6 cells transfected with mutant cell surface expressed channel receptors and assays using the transfected cells
AU2003281169A1 (en)	2002-07-17	2004-02-02	Warner-Lambert Company Llc	Combination of an allosteric carboxylic inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib
DE10234424A1 (de)	2002-07-29	2004-02-12	Bayer Ag	Benzothiophen-, Benzofuran- und Indolharnstoffe
WO2004014377A1 (en)	2002-08-13	2004-02-19	Warner-Lambert Company Llc	4-hydroxyquinoline derivatives as matrix metalloproteinase inhibitors
AU2003253186A1 (en)	2002-08-13	2004-02-25	Warner-Lambert Company Llc	Fused tetrahydropyridine derivatives as matrix metalloproteinase inhibitors
GB0220581D0 (en)	2002-09-04	2002-10-09	Novartis Ag	Organic Compound
MXPA05003317A (es)	2002-09-25	2005-07-05	Memory Pharm Corp	Indazoles, benzotiazoles y benzoisotiazoles asi como preparacion y usos de los mismos.
PL377777A1 (pl)	2002-12-11	2006-02-20	Pharmacia & Upjohn Company Llc	Leczenie chorób połączeniami agonistów receptora alfa 7-nikotynowego i innych związków
US20050031651A1 (en)	2002-12-24	2005-02-10	Francine Gervais	Therapeutic formulations for the treatment of beta-amyloid related diseases
WO2004085433A2 (en)	2003-03-28	2004-10-07	Pharmacia & Upjohn Company Llc	Positive allosteric modulators of the nicotinic acetylcholine receptor
US20050119249A1 (en)	2003-12-02	2005-06-02	Erik Buntinx	Method of treating neurodegenerative diseases using D4 and 5-HT2A antagonists, inverse agonists or partial agonists
US20050245531A1 (en)	2003-12-22	2005-11-03	Abbott Laboratories	Fused bicycloheterocycle substituted quinuclidine derivatives
WO2006065233A1 (en)	2004-12-10	2006-06-22	Abbott Laboratories	Fused bicycloheterocycle substituted quinuclidine derivatives
EP1735306A2 (en)	2004-03-25	2006-12-27	Memory Pharmaceuticals Corporation	Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, and preparation and uses thereof
CN101312968A (zh)	2005-09-23	2008-11-26	记忆药物公司	吲唑、苯并噻唑、苯并异噻唑、苯并异噁唑、吡唑并吡啶、异噻唑并吡啶及其制备和用途
ES2555803T3 (es)	2006-10-23	2016-01-08	Cephalon, Inc.	Fusión de derivados bicíclicos 2,4-diaminopirimidina como utilizar inhibidores ALK y c-Met
RS52166B (sr)	2007-05-11	2012-08-31	Pfizer Inc.	Amino-heterociklična jedinjenja
BRPI0815773A2 (pt)	2007-08-31	2019-09-24	Eisai R&D Man Co Ltd	composto, e, medicamento.
US7935815B2 (en)	2007-08-31	2011-05-03	Eisai R&D Management Co., Ltd.	Imidazoyl pyridine compounds and salts thereof
WO2009046025A1 (en)	2007-10-01	2009-04-09	Comentis, Inc.	Quinuclidin-4-ylmethyl 1h-indole-3-carboxylate derivatives as alpha 7 nicotinic acetylcholine receptor ligands for the treatment of alzheimer's disease
WO2009067579A1 (en)	2007-11-21	2009-05-28	Abbott Laboratories	Biaryl substituted azabicyclic alkane derivatives as nicotinic acetylcholine receptor activity modulators
PL2282778T3 (pl)	2008-04-29	2017-08-31	Pharnext	Nowe podejścia terapeutyczne do leczenia choroby alzheimera i powiązanych zaburzeń poprzez modulację angiogenezy
WO2009133128A1 (en)	2008-04-29	2009-11-05	Pharnext	Combination compositions for treating alzheimer disease and related disorders with zonisamide and acamprosate
DK2282779T3 (da)	2008-04-29	2013-05-27	Pharnext	Nye terapeutiske fremgangsmåder til behandling af alzheimer sygdom og beslægtede lidelser gennem en modulation af cellestress-respons
NZ593090A (en)	2008-11-13	2013-06-28	Link Medicine Corp	Azaquinolinone derivatives and uses thereof
LT2889033T (lt)	2008-11-19	2018-07-10	Forum Pharmaceuticals Inc.	Šizofrenijos negatyvių simptomų gydymas (r)-7-chlor-n-(chinuklidin-3-il)benzo[b]tiofen-2-karboksamidu ir jo farmaciniu požiūriu priimtinomis druskomis
WO2010071846A2 (en)	2008-12-19	2010-06-24	Afraxis, Inc.	Compounds for treating neuropsychiatric conditions
JP2012514011A (ja)	2008-12-30	2012-06-21	ラモトアトテルーアビブユニバーシティーリミテッド	Ｎａｐを用いる併用治療の方法
TWI404721B (zh)	2009-01-26	2013-08-11	Pfizer	胺基－雜環化合物
TR201908314T4 (tr)	2009-02-20	2019-06-21	2 Bbb Medicines B V	Glutatyon bazlı ilaç dağıtım sistemi.
CA2753696A1 (en)	2009-02-26	2010-09-02	Noritaka Kitazawa	Nitrogen-containing fused heterocyclic compounds and their use as beta amyloid production inhibitors
CA2758321A1 (en)	2009-04-13	2010-10-21	Theravance, Inc.	5-ht4 receptor agonist compounds for treatment of cognitive disorders
WO2010141932A1 (en)	2009-06-05	2010-12-09	Link Medicine Corporation	Aminopyrrolidinone derivatives and uses thereof
WO2011057199A1 (en)	2009-11-06	2011-05-12	Adenios, Inc.	Compositions for treating cns disorders
US20110274628A1 (en)	2010-05-07	2011-11-10	Borschke August J	Nicotine-containing pharmaceutical compositions

2009
- 2009-11-19 LT LTEP15151165.6T patent/LT2889033T/lt unknown
- 2009-11-19 EP EP09756921A patent/EP2355822B1/en active Active
- 2009-11-19 PL PL15151165T patent/PL2889033T3/pl unknown
- 2009-11-19 CA CA2744278A patent/CA2744278C/en not_active Expired - Fee Related
- 2009-11-19 RS RS20120560A patent/RS52583B/sr unknown
- 2009-11-19 DK DK12185913.6T patent/DK2540297T3/en active
- 2009-11-19 RU RU2011124515/15A patent/RU2532327C2/ru not_active IP Right Cessation
- 2009-11-19 HR HRP20130007AT patent/HRP20130007T1/hr unknown
- 2009-11-19 PT PT97569214T patent/PT2355822E/pt unknown
- 2009-11-19 PL PL12185913T patent/PL2540297T3/pl unknown
- 2009-11-19 AU AU2009316557A patent/AU2009316557B2/en not_active Ceased
- 2009-11-19 PT PT121859136T patent/PT2540297E/pt unknown
- 2009-11-19 TR TR2018/07944T patent/TR201807944T4/tr unknown
- 2009-11-19 NZ NZ613291A patent/NZ613291A/en not_active IP Right Cessation
- 2009-11-19 SI SI200931223T patent/SI2540297T1/sl unknown
- 2009-11-19 SI SI200930466T patent/SI2355822T1/sl unknown
- 2009-11-19 SI SI200931855T patent/SI2889033T1/en unknown
- 2009-11-19 EP EP12185913.6A patent/EP2540297B1/en active Active
- 2009-11-19 NZ NZ593467A patent/NZ593467A/xx not_active IP Right Cessation
- 2009-11-19 BR BRPI0922057A patent/BRPI0922057A2/pt not_active Application Discontinuation
- 2009-11-19 EP EP15151165.6A patent/EP2889033B1/en active Active
- 2009-11-19 KR KR1020117013996A patent/KR20110091549A/ko not_active Ceased
- 2009-11-19 DK DK15151165.6T patent/DK2889033T3/en active
- 2009-11-19 PT PT151511656T patent/PT2889033T/pt unknown
- 2009-11-19 SM SM20180308T patent/SMT201800308T1/it unknown
- 2009-11-19 MY MYPI2011002245A patent/MY159826A/en unknown
- 2009-11-19 CA CA2894860A patent/CA2894860C/en not_active Expired - Fee Related
- 2009-11-19 PE PE2011001056A patent/PE20110711A1/es not_active Application Discontinuation
- 2009-11-19 KR KR1020187002503A patent/KR20180011888A/ko not_active Ceased
- 2009-11-19 MX MX2011005270A patent/MX2011005270A/es active IP Right Grant
- 2009-11-19 CN CN201610021941.2A patent/CN105687191A/zh active Pending
- 2009-11-19 JP JP2011537621A patent/JP5272080B2/ja not_active Expired - Fee Related
- 2009-11-19 HU HUE12185913A patent/HUE026815T2/en unknown
- 2009-11-19 PL PL09756921T patent/PL2355822T3/pl unknown
- 2009-11-19 KR KR1020147032489A patent/KR20140146216A/ko not_active Ceased
- 2009-11-19 HU HUE15151165A patent/HUE037938T2/hu unknown
- 2009-11-19 US US13/129,782 patent/US8642638B2/en not_active Expired - Fee Related
- 2009-11-19 MY MYPI2014003208A patent/MY173229A/en unknown
- 2009-11-19 CN CN2009801546937A patent/CN102281878A/zh active Pending
- 2009-11-19 EP EP18152484.4A patent/EP3357495B1/en active Active
- 2009-11-19 ES ES09756921T patent/ES2396300T3/es active Active
- 2009-11-19 ES ES12185913.6T patent/ES2541528T3/es active Active
- 2009-11-19 DK DK09756921.4T patent/DK2355822T3/da active
- 2009-11-19 ES ES15151165.6T patent/ES2673016T3/es active Active
- 2009-11-19 CA CA3017886A patent/CA3017886A1/en not_active Abandoned
- 2009-11-19 CN CN201610020803.2A patent/CN105687190A/zh active Pending
- 2009-11-19 SG SG10201504102QA patent/SG10201504102QA/en unknown
- 2009-11-19 WO PCT/US2009/065173 patent/WO2010059844A1/en not_active Ceased
2011
- 2011-05-16 IL IL212921A patent/IL212921A/en not_active IP Right Cessation
- 2011-05-19 CL CL2011001178A patent/CL2011001178A1/es unknown
- 2011-05-19 CO CO11061800A patent/CO6400190A2/es not_active Application Discontinuation
- 2011-05-20 CR CR20110267A patent/CR20110267A/es unknown
- 2011-05-23 EC EC2011011076A patent/ECSP11011076A/es unknown
- 2011-05-31 ZA ZA2011/04044A patent/ZA201104044B/en unknown
2012
- 2012-11-12 US US13/674,290 patent/US8569354B2/en not_active Expired - Fee Related
2013
- 2013-01-07 CY CY20131100013T patent/CY1113671T1/el unknown
- 2013-01-09 SM SM201300003T patent/SMT201300003B/it unknown
- 2013-04-17 JP JP2013086454A patent/JP5674854B2/ja not_active Expired - Fee Related
- 2013-12-23 US US14/139,178 patent/US20140148479A1/en not_active Abandoned
2014
- 2014-02-07 US US14/175,654 patent/US8815933B2/en not_active Expired - Fee Related
- 2014-06-04 RU RU2014122858A patent/RU2662560C2/ru not_active IP Right Cessation
- 2014-07-17 PH PH12014501629A patent/PH12014501629A1/en unknown
- 2014-10-08 US US14/509,305 patent/US20150265583A1/en not_active Abandoned
- 2014-11-26 JP JP2014238660A patent/JP5869653B2/ja not_active Expired - Fee Related
2015
- 2015-07-01 HR HRP20150711TT patent/HRP20150711T1/hr unknown
- 2015-07-02 CY CY20151100575T patent/CY1116460T1/el unknown
- 2015-07-10 SM SM201500167T patent/SMT201500167B/it unknown
- 2015-10-12 IL IL242035A patent/IL242035A0/en unknown
- 2015-10-12 IL IL242034A patent/IL242034A/en not_active IP Right Cessation
2016
- 2016-01-07 JP JP2016001812A patent/JP6223480B2/ja not_active Expired - Fee Related
2017
- 2017-07-18 CL CL2017001853A patent/CL2017001853A1/es unknown
- 2017-10-03 JP JP2017193867A patent/JP2018039818A/ja active Pending
- 2017-10-27 US US15/796,475 patent/US20180271844A1/en not_active Abandoned
- 2017-12-06 IL IL256140A patent/IL256140A/en unknown
- 2017-12-14 IL IL256313A patent/IL256313A/en unknown
2018
- 2018-01-03 PH PH12018500023A patent/PH12018500023A1/en unknown
- 2018-05-25 CL CL2018001420A patent/CL2018001420A1/es unknown
- 2018-06-18 HR HRP20180942TT patent/HRP20180942T1/hr unknown
- 2018-06-20 CY CY20181100638T patent/CY1121607T1/el unknown
- 2018-07-11 RU RU2018125456A patent/RU2018125456A/ru unknown
2019
- 2019-11-22 JP JP2019210985A patent/JP2020040977A/ja active Pending

Also Published As

Publication number	Publication date
SMT201300003B (it)	2013-05-06
KR20110091549A (ko)	2011-08-11
US20150265583A1 (en)	2015-09-24
CY1116460T1 (el)	2017-03-15
IL242034A (en)	2017-12-31
ZA201104044B (en)	2012-11-28
CA2744278C (en)	2015-09-08
RU2011124515A (ru)	2012-12-27
SMT201500167B (it)	2015-09-07
US20140148479A1 (en)	2014-05-29
ES2541528T3 (es)	2015-07-21
PE20110711A1 (es)	2011-10-11
CA3017886A1 (en)	2010-05-27
KR20180011888A (ko)	2018-02-02
DK2540297T3 (en)	2015-07-13
EP2355822B1 (en)	2012-10-10
US20140155430A1 (en)	2014-06-05
JP6223480B2 (ja)	2017-11-01
DK2355822T3 (da)	2013-01-28
HRP20130007T1 (hr)	2013-01-31
SMT201800308T1 (it)	2018-09-13
JP2016128442A (ja)	2016-07-14
US20180271844A1 (en)	2018-09-27
EP2889033B1 (en)	2018-03-21
CN105687191A (zh)	2016-06-22
HUE026815T2 (en)	2016-07-28
IL242034A0 (en)	2015-11-30
CA2894860C (en)	2018-11-06
SI2540297T1 (sl)	2015-08-31
PL2889033T3 (pl)	2018-10-31
CR20110267A (es)	2011-10-13
CL2017001853A1 (es)	2018-05-11
WO2010059844A1 (en)	2010-05-27
CN105687190A (zh)	2016-06-22
BRPI0922057A2 (pt)	2015-12-15
US8642638B2 (en)	2014-02-04
HK1158520A1 (en)	2012-07-20
EP3357495B1 (en)	2019-12-25
SI2355822T1 (sl)	2013-02-28
EP2540297B1 (en)	2015-04-08
IL242035A0 (en)	2015-11-30
ES2396300T3 (es)	2013-02-20
JP5869653B2 (ja)	2016-02-24
PH12018500023A1 (en)	2019-07-15
LT2889033T (lt)	2018-07-10
PL2355822T3 (pl)	2013-03-29
CA2744278A1 (en)	2010-05-27
JP5674854B2 (ja)	2015-02-25
IL256140A (en)	2018-02-28
JP2015083574A (ja)	2015-04-30
KR20140146216A (ko)	2014-12-24
US20130137717A1 (en)	2013-05-30
SI2889033T1 (en)	2018-08-31
RU2014122858A (ru)	2015-12-10
US8569354B2 (en)	2013-10-29
HRP20150711T1 (hr)	2015-08-14
PT2540297E (pt)	2015-08-26
JP5272080B2 (ja)	2013-08-28
SG10201504102QA (en)	2015-06-29
HRP20180942T1 (hr)	2018-08-10
IL212921A0 (en)	2011-07-31
HUE037938T2 (hu)	2018-09-28
RU2662560C2 (ru)	2018-07-26
JP2012509347A (ja)	2012-04-19
ES2673016T3 (es)	2018-06-19
CY1121607T1 (el)	2020-05-29
IL212921A (en)	2015-11-30
PL2540297T3 (pl)	2015-12-31
EP3357495A1 (en)	2018-08-08
ECSP11011076A (es)	2011-09-30
MY159826A (en)	2017-02-15
EP2355822A1 (en)	2011-08-17
PH12014501629B1 (en)	2016-01-18
JP2020040977A (ja)	2020-03-19
PH12014501629A1 (en)	2016-01-18
US20110288119A1 (en)	2011-11-24
RU2018125456A (ru)	2020-01-13
AU2009316557A1 (en)	2010-05-27
JP2013166771A (ja)	2013-08-29
AU2009316557B2 (en)	2015-08-27
US8815933B2 (en)	2014-08-26
NZ613291A (en)	2014-11-28
CY1113671T1 (el)	2016-07-27
IL256313A (en)	2018-02-28
RU2532327C2 (ru)	2014-11-10
PT2889033T (pt)	2018-06-18
EP2540297A1 (en)	2013-01-02
JP2018039818A (ja)	2018-03-15
MY173229A (en)	2020-01-07
RS52583B (sr)	2013-04-30
MX2011005270A (es)	2011-08-03
TR201807944T4 (tr)	2018-06-21
DK2889033T3 (en)	2018-07-02
EP2889033A1 (en)	2015-07-01
NZ593467A (en)	2013-07-26
PT2355822E (pt)	2013-01-14
CN102281878A (zh)	2011-12-14
CO6400190A2 (es)	2012-03-15
CL2018001420A1 (es)	2018-09-28
CA2894860A1 (en)	2010-05-27

Publication	Publication Date	Title
CL2011001178A1 (es)	2011-10-14	Uso de (r)-7-cloro-niquinuclidin-3-1l)senzo[b]tiofen0-2-carboxamida o una sal de la misma o una composicion farmaceutica que la comprende para preparar un medicamento util para mejorar la cognicion en un paciente que sufre de alzheimer o esquizofrenia.
UY35624A (es)	2015-01-30	Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington
EA201270221A1 (ru)	2012-08-30	Лечение болезни крона с применением лаквинимода
EA201290026A1 (ru)	2012-07-30	Способ лечения пациента, имеющего риск развития язвы, связанной с приемом нестероидных противовоспалительных средств (nsaid)
BRPI1011031A2 (pt)	2016-08-16	sal de arginina de um agente ativo, composição líquida ou em gel farmaceuticamente aceitável, kit, método para tratamento de uma desordem neurológica e método para tratar ou amenizar a doença de parkinson em um paciente que necessite deste.
PE20212245A1 (es)	2021-11-24	Composicion farmaceutica oral que comprende acido 3-[5-(2-fluorofenil)- [1,2,4]oxadiazol-3-il]-benzoico
BR112015029512A2 (pt)	2017-07-25	derivados de pirazolopirrolidina e seu uso no tratamento de doenças
BR112015029491A2 (pt)	2017-07-25	derivados de imidazopirrolidinona e seu uso no tratamento de doença
BRPI0507966A (pt)	2007-07-17	uso de meloxicam para o tratamento de doenças respiratórias em porcos
UA106636C2 (uk)	2014-09-25	Морфолінотіазоли як позитивні алостеричні модулятори альфа 7
BR112014016085A2 (pt)	2017-06-13	composições aprimoradas e métodos para distribuição de omeprazol mais ácido acetilsalicílico
CL2011002847A1 (es)	2012-07-20	Uso de (r)-7-cloro-n-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida o una sal farmaceuticamente aceptable del mismo y un inhibidor de acetilcolinesterasa para preparar un medicamento util para mejorar la cognicion.
BR112015018252A2 (pt)	2017-07-18	composição farmacêutica aquosa de dose fixa estável para administração nasal para um ser humano, composição de suspensão aquosa farmacêutica de dose fixa estável para administração nasal para um ser humano, suspensão estável adequada para administração nasal a um ser humano, método para tratar rinite em um ser humano necessitando do mesmo, uso da composição farmacêutica para administração nasal, método para liberar uma composição farmacêutica e kit
FI3504187T3 (fi)	2025-04-05	Pridopidiinin käyttö toiminnallisen heikkenemisen hoitoa varten
BRPI0418026A (pt)	2007-04-17	derivados de fenilalanina ou sais farmaceuticamente aceitáveis destes, composição farmacêutica, antagonista de alfa4 integrina, e, agente terapêutico ou agente preventivo para doenças
UA115648C2 (uk)	2017-12-11	Доставка терапевтичних агентів до цнс
BR112015029401A8 (pt)	2020-03-17	derivados de pirazolo-pirrolidin-4-ona, seus usos, e composição e combinação farmacêuticas
AR075735A1 (es)	2011-04-20	Composiciones farmaceuticas de liberacion inmediata que comprenden oxicodona y naloxona. uso
CL2011002858A1 (es)	2012-06-22	Uso de una composicion farmaceutica transmucosa oral que comprende dexmedetomidina y una sal farmaceuticamente aceptable y un excipiente farmaceuticamente aceptable para preparar un medicamento util para tratar o prevenir el dolor.
AR070025A1 (es)	2010-03-10	Uso de derivados de 1-amino-alquilciclohexano para el tratamiento del tinnitus coclear y composicion farmaceutica
BR112012003283A8 (pt)	2016-05-17	sal farmaceuticamente aceitável de um agente fotossensibilizante anfifílico, composição farmacêutica, produto, kit, uso de um sal farmaceuticamente aceitável de um agente fotossensibilizante anfifílico, e, método de introdução de uma molécula de medicamento no citosol de uma célula em um paciente.
NZ587202A (en)	2013-03-28	Methods for measuring a patient response upon administration of a drug and compositions thereof
AR090885A1 (es)	2014-12-10	Uso de laquinimod en alta dosis para el tratamiento de la esclerosis multiple
CL2011001927A1 (es)	2012-07-20	Uso de una composicion farmaceutica de liberacion sostenida, que comprende como ingrediente activo a 4-aminopiridina, que sirve para preparar un medicamento util para el tratamiento de la esclerosis multiple, en dos dosis de 10 miligramos diarias, que permite recuperar la marcha de un paciente afectado.
PE20081751A1 (es)	2008-12-27	Composicion farmaceutica que comprende un antagonista muscarinico y antagonista beta-2 adrenorreceptor